BRIEF-Galapagos to get 34 mln euro milestone payment from GSK

BRUSSELS Wed Nov 27, 2013 1:41am EST

Related Topics

BRUSSELS Nov 27 (Reuters) - Galapagos NV : * GSK to initiate exploratory Phase 2 study with GSK2586184 in patients with

ulcerative colitis * Ulcerative colitis is a third indication for this investigational molecule,

in addition to psoriasis and lupus * To receive from GSK 34 mln euros, and up to double-digit royalties on commercial sales of GSK2586184

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.